Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2022-04-27 Regulatory Filings
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
425 Filing
Regulatory Filings
2022-04-27 English
10-K/A
Annual Report FY 2021
2022-04-21 English
10-K
Annual Report FY 2021
2022-03-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 22, 2022. It references a press release about financial results for the fiscal year ended December 31, 2021, and includes a slide presentation for investor and industry conferences. The document explicitly states that the press release and presentation are furnished as exhibits and are not "filed" for purposes of Section 18, indicating this is an announcement rather than the full financial report itself. The length is 4051 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. The content primarily announces the release of financial results and an upcoming conference call, which aligns with a Regulatory Filing (RNS) rather than an Annual Report (10-K) or Earnings Release (ER). Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-03-22 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The key content is under Item 5.02, which reports the resignation of a senior officer (Chief Legal Officer, Senior VP, Corporate Secretary). This is an announcement of a change in senior management. The document does not contain financial data or detailed reports but rather a notification of management change. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3059 characters, which is typical for such announcements. Hence, the classification is MANG with high confidence.
2022-02-25 English
8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 18, 2022, by Caladrius Biosciences, Inc. The key content is a notice from Nasdaq that the company's stock has not met the minimum bid price requirement for continued listing. The document discusses the grace period for compliance and potential consequences if compliance is not met. This is a regulatory announcement about a potential delisting event, specifically under Item 3.01 which relates to delisting or failure to satisfy continued listing standards. The document is not a full report but a current report notifying the market of this issue. Therefore, the appropriate classification is a Delisting Announcement (DLST). The document length is 4311 characters, which is consistent with a short regulatory announcement rather than a full report.
2022-02-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.